Assay profiling targeted towards companies and organisations involved in metabolism research and the development of new drugs
Lipomics Technologies, a company specialising in the comprehensive and quantitative profiling of lipid metabolites, has announced the availability of a new acylcarnitine profiling platform that will help accelerate the pace of drug discovery and development for a wide range of critical diseases and metabolic conditions.
Acylcarnitines are intermediates in mitochondrial beta-oxidation or 'fat burning'.
Their measurement in serum or plasma provides information on changes in lipid metabolism related to obesity, exercise, stress response and myopathies.
The LC-MS based method provides quantitative data on short and long chain acylcarnitines as well as free carnitine.
"Quantitative acylcarnitine profiling provides an insight into changes in mitochondrial energetics influenced by disease, drug treatment and lifestyle", said chief scientific officer, Steve Watkins.
"Acylcarnitine profiling is an excellent complement to our existing assays".
"We can now provide our customers with a more comprehensive understanding of lipids and their role in metabolic diseases, enhancing all phases of pharmaceutical research from screening new compounds to clinical trials."
